Qiagen launches digital PCR assays for microbial applications
June 13, 2024—Qiagen has launched 35 wet-lab tested digital PCR microbial DNA detection assays for its digital PCR platform QIAcuity.
Webinars and Sponsored Roundtables — Register Now
Thursday, April 30, 2026, 11:00 AM–12:00 PM ET
Hear an expert discuss how Memorial Sloan Kettering Cancer Center (MSKCC) is utilizing
the oncoReveal® Nexus 21-gene panel to redefine turnaround time and actionable insights
in cancer care. Dr. Ewalt shares a perceptive look at the clinical need for rapid, front-line NGS sequencing, and how a unique, purpose built targeted NGS panel (Pillar Biosciences’ oncoReveal Nexus 21 gene Panel) was developed, validated and implemented clinically by Memorial Sloan Kettering Cancer Center (MSK-REACT) to complement their current comprehensive genomic profiling (CGP) approach.
Webinar presenter Mark Ewalt, MD, Associate Medical Director for Laboratory Operations for Diagnostic Molecular Pathology in the Molecular Diagnostics Service, Department of Pathology and Laboratory Medicine, MSKCC.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Pillar Biosciences.
Thursday, May 28, 2026, 1:00–2:00 PM ET
This session is designed to improve understanding and application of recent updates to synoptic pathology reporting protocols such as the latest Reporting Template for Reporting Results of Biomarker Testing of Specimens from Patients with Carcinoma of the Breast. These changes reflect evolving clinical guidelines that directly influence diagnostic accuracy and treatment selection in breast cancer care.
Webinar presenters Thaer Khoury, MD, FCAP, Chair, Pathology and Laboratory Medicine, Roswell Park Comprehensive Cancer Cente, and Colin Murphy, CEO of mTuitive.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Subspecialties
Interactive Product Guides
CAP TODAY
SignUpAdvertiserForm
Subscribe * indicates required Email Address * First Name Last Name Country
Bio-Rad launches GBS positive, negative run controls
June 11, 2024—Bio-Rad Laboratories has launched its Exact Diagnostics GBS positive and negative run controls.
Liaison Plex Yeast Blood Culture assay gets 510(k) clearance
June 7, 2024—Diasorin announced it has received 510(k) clearance from the FDA for the company’s Liaison Plex Yeast Blood Culture assay, the second molecular multiplexing panel on the Liaison Plex.
FDA clears Horiba Yumizen H2500 hematology analyzer
June 6, 2024—Horiba has announced that its high-throughput Yumizen H2500 hematology analyzer has received FDA 510(k) clearance and is available for sale in the United States.
Epredia SlideMate Laser gets MedTech Breakthrough Award
June 3, 2024—MedTech Breakthrough announced that Epredia has been selected as the winner of best new technology solution—pathology for its SlideMate Laser printer in the 8th annual MedTech Breakthrough Awards program.
What is flock? Find out what makes Puritan® flocked swabs so special.
Puritan® patented flocked swabs are super collectors! PurFlock Ultra® and HydraFlock® flocked swabs, incorporating intricate fiber technology, are developed and designed for increased absorbency and elution capacity. LEARN MORE.
Recordati Rare Diseases introduces educational website
May 2024—Recordati Rare Diseases has introduced its new educational website, Think iMCD, at https://thinkimcd.us. The platform is tailored for pathologists and offers comprehensive support for the diagnostic process of idiopathic multicentric Castleman disease (iMCD). The website provides an overview of iMCD diagnostic criteria, practical steps for assessing lymph node biopsies, and links to additional resources for understanding CD/iMCD. Designed to enhance professional awareness and comprehension, the site aims to be a valuable tool for the medical community.
ACLA challenges FDA final rule to regulate LDTs
May 29, 2024—The American Clinical Laboratory Association and its member company, HealthTrackRx, filed a lawsuit today against the U.S. Food and Drug Administration in the U.S. District Court for the Eastern District of Texas, challenging the agency’s May 6 final rule, which seeks to regulate professional laboratory testing services as medical devices under the Federal Food, Drug, and Cosmetic Act.
FDA clears BioMérieux Vidas TBI test
May 28, 2024—BioMérieux received FDA 510(k) clearance for its Vidas TBI (GFAP, UCH-L1), a serum-based test that supports the assessment of patients with mild traumatic brain injury, including concussion.